GlaxoSmithKline makes bold move with £130m Covid-19 investment | Nils Pratley

GSK’s share price has been left standing by AstraZeneca’s high-risk success in cancer treatments

Monday’s most important vaccine news was the promising early data from the Oxford University and AstraZeneca coronavirus trial – “robust immune responses” is encouraging. But let’s not overlook other vaccine developments. The industry has been viewed for years as a dull subsector of the pharmaceutical business; now it is a whir of deal-making activity.

GlaxoSmithKline, already one of the world’s biggest vaccine makers, leaped into action by paying £130m for a 10% stake in German group CureVac, the company that briefly registered on President Trump’s radar (he suggested the US should buy the firm for its Covid-19 possibilities).

Continue reading…